Author

A. M. Kurimchak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Approach:experimental assay· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. S. Duncan· 4 shared D. Araiza-Olivera· 2 shared K. J. Johnson· 2 shared K. Q. Cai· 2 shared S. Peri· 2 shared A. C. Cannon· 1 shared A. D. Jermakowicz· 1 shared A. M. Jermakowicz· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. S. Duncan

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

RAPID RESISTANCE TO BET INHIBITORS IS MEDIATED BY FGFR1 IN GLIOBLASTOMA

A. M. Jermakowicz, A. M. Kurimchak, K. J. Johnson, F. Bourgain-Guglielmetti, S. Kaeppeli, M. Affer, H. Pradhyumnan, R. Suter, W. Walters, M. Cepero, J. Duncan, N. G. Ayad

This study identifies rapid resistance to BET inhibitors in glioblastoma mediated by FGFR1 and shows that co-targeting BET and FGFR1 synergizes to reduce tumor growth.

bioRxiv · Dec 19, 2023Cancer Biology

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

A. C. Cannon, K. Budagyan, C. Uribe-Alvarez, A. M. Kurimchak, D. Araiza-Olivera, K. Q. Cai, S. Peri, Y. Zhou, J. S. Duncan, J. Chernoff

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

A. M. Kurimchak, C. Herrera-Montavez, S. Montserrat-Sangra, D. Araiza-Olivera, J. Hu, J. Jin, J. S. Duncan

This study identifies MDR1 as a mediator of resistance to PROTACs in cancer cells and shows that combining MDR1 inhibitors with PROTACs enhances drug efficacy.

bioRxiv · Dec 2, 2021Cancer Biology

Multiplex-inhibitor bead mass spectrometry reveals differential kinome signatures in newly diagnosed and recurrent glioblastoma

A. D. Jermakowicz, A. M. Kurimchak, J. Sarkaria, R. Komotar, M. E. Ivan, S. Schürer, J. S. Duncan, N. Ayad

This study uses MIB-MS to compare kinase profiles between newly diagnosed and recurrent glioblastoma, identifying differences in signaling pathways associated with tumor recurrence.

bioRxiv · Sep 21, 2020 · PreprintCancer Biology

Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 As Candidate Therapeutic Target

K. J. Johnson, V. Kumar, A. M. Kurimchak, N. Srivastava, S. Peri, K. Q. Cai, G. M. Mantia-Smaldone, J. S. Duncan

The paper develops a SILAC-based MIB-MS workflow to profile the kinome in endometrial tumors, identifying SRPK1 as a potential therapeutic target.

bioRxiv · Mar 3, 2020Cancer Biology